ASCO26: AstraZeneca unveils data it hopes will persuade FDA to approve oral SERD on June 03, 2026 Approved ASCO26 AstraZeneca camizestrant Clearance ctDNA ESR1 gene HR+ Malignant neoplasm of breast Mutation Oncologic Drugs Advisory Committee oral SERD SERENA-6 trial United States Food and Drug Administration +
AstraZeneca Details Its Oral SERD 'Switching' Regimen Amid Feasibility Questions on June 01, 2025 AstraZeneca camizestrant CDK4/6 inhibitor Disease Progression ESR1 gene Malignant neoplasm of breast Mutation oral SERD SERENA-6 trial treatment resistance +